Trial reportSurgical endoscopy2017
Transoral fundoplication offers durable symptom control for chronic GERD: 3-year report from the TEMPO randomized trial with a crossover arm.
Trial report in Surgical endoscopy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Impact of second-generation transoral incisionless fundoplication on atypical GERD symptoms: a systematic review and meta-analysis.Gastrointestinal endoscopy · 2023Pooled it
- Trial
- The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective.Surgical innovation · 2018Trial
- Diagnostic and Management Approach to Reflux-Related Cough.Gastroenterology & hepatology · 2026Article
- Current pharmacological and procedural treatments for gastro-oesophageal reflux disease: comprehensive review.BJS open · 2025Review
- Transoral incisionless fundoplication as rescue therapy for gastroesophageal reflux in a lung transplant recipient.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2025Article
- Endoscopic full-thickness plication along with argon plasma coagulation for treatment of proton pump inhibitor dependent gastroesophageal reflux disease.World journal of gastrointestinal endoscopy · 2024Article
- From Scalpel to Scope: How Surgical Techniques Made Way for State-of-The-Art Endoscopic Procedures.Gastro hep advances · 2024Review
- Hybrid hiatal hernia repair: is it cost-effective?Journal of robotic surgery · 2022Article
- Recent Advances in the Endoscopic Management of Gastro-esophageal Reflux Disorder: A Review of Literature.Cureus · 2022Review
- Update on the Use of Transoral Incisionless Fundoplication for the Treatment of Gastroesophageal Reflux Disease.Gastroenterology & hepatology · 2021Article
- Peroral endoscopic myotomy: techniques and outcomes.Shanghai chest · 2021Article
- Endoscopic and Surgical Treatments for Achalasia: Who to Treat and How?Gastroenterology clinics of North America · 2020Review
- Management of Barrett's esophagus with dysplasia refractory to radiofrequency ablation.World journal of gastroenterology · 2020Review
- The evolution of TIF: transoral incisionless fundoplication.Therapeutic advances in gastroenterology · 2020Review
- Transoral incisionless fundoplication with EsophyX for gastroesophageal reflux disease: clinical efficacy is maintained up to 10 years.Endoscopy international open · 2019Article
- Long-term reported outcomes of transoral incisionless fundoplication: an 8-year cohort study.Surgical endoscopy · 2019Article
- Transoral incisional fundoplication for reflux after peroral endoscopic myotomy: a crucial addition to our arsenal.Endoscopy international open · 2018Article
- Endoscopic Treatments of GERD.Current treatment options in gastroenterology · 2018Review
- Transoral incisionless fundoplication for Jehovah's Witnesses: A case report discussing safety and durability.SAGE open medical case reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFour randomized controlled trials have demonstrated the short-term efficacy and safety of transoral esophagogastric fundoplication (TF) performed with the EsophyX
methodsThe TF EsophyX versus Medical PPI Open Label trial was conducted in seven US sites. Between June and August 2012, we enrolled patients with small (<2 cm) or absent hiatal hernias who suffered from troublesome GERD symptoms while on PPI therapy for at least 6 months and had abnormal esophageal acid exposure (EAE). Randomization was to TF group (n = 40) or to PPI group (n = 23). Following evaluation at 6 months, all remaining PPI patients (n = 21) elected to undergo crossover to TF. Fifty-two patients were assessed at 3 years for (1) GERD symptom resolution using three GERD-specific quality of life questionnaires, (2) healing of esophagitis using endoscopy, (3) EAE using 48-h Bravo testing, and (4) discontinuation of PPI use. Two patients who underwent revisional procedures by year 3 were included in the final analysis.
resultsAt 3-year follow-up, elimination of troublesome regurgitation and all atypical symptoms was reported by 90 % (37/41) and 88 % (42/48) of patients, respectively. The mean Reflux Symptom Index score improved from 22.2 (9.2) on PPIs at screening to 4 (7.1) off PPIs 3 years post-TF, p < 0.0001. The mean total % time pH <4 improved from 10.5 (3.5) to 7.8 (5.7), p = 0.0283. Esophagitis was healed in 86 % (19/22) of patients. At the end of study, 71 % (37/52) of patients had discontinued PPI therapy. All outcome measures remained stable between 1-, 2-, and 3-year follow-ups.
conclusionThis study demonstrates that TF can be used to achieve long-term control of chronic GERD symptoms, healing of esophagitis, and improvement in EAE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.